Zoetis Inc.

Company Overview

Business Model: Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health. The company supports veterinarians, pet owners, and livestock producers worldwide by pioneering ways to predict, prevent, detect, and treat animal illness. Its diversified portfolio spans eight core species (dogs, cats, horses, cattle, swine, poultry, fish, and sheep) and seven major product categories (parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics). Companion animal products generated approximately 70% of total revenue in 2025, while livestock products accounted for approximately 29%. Revenue is primarily generated through sales to veterinarians and livestock producers, either directly or via third-party distributors, with a growing presence in retail and e-commerce channels.

Market Position: Zoetis Inc. holds the largest revenue-based market position in the animal health industry, maintaining leadership across nearly all major operating regions. The company's competitive advantages stem from its extensive research and development (R&D) capabilities, a global manufacturing network of 21 owned sites complemented by over 90 contract manufacturing organizations (CMOs), and a large sales organization comprising approximately 3,900 employees. In 2025, the top two product lines, Simparica/Simparica Trio and Apoquel/Apoquel Chewable, contributed approximately 16% and 12% of total revenue, respectively. The top five product lines, including Cytopoint, Librela, and the ceftiofur line, collectively accounted for approximately 42% of revenue, while the top ten product lines contributed approximately 57%.

Recent Strategic Developments: Zoetis Inc. continues to enhance its portfolio through strategic acquisitions and innovation. In 2025, the company acquired Veterinary Pathology Group, a veterinary diagnostic laboratory group in the U.K. and Ireland. This follows the 2023 acquisitions of PetMedix Ltd (U.K.) and adivo GmbH (Germany), both biopharmaceutical companies focused on antibody-based therapeutics for companion animals. The company has also expanded its Vetscan Imagyst diagnostic platform, adding artificial intelligence (AI) dermatology and AI fecal for equine in 2023, AI urine sediment analysis and Vetscan OptiCell in 2024, and AI Masses in 2025. In 2024, Zoetis Inc. initiated a collaboration with Blacksmith Medicines to discover and develop novel antibiotics for animal health. The company divested its medicated feed additive product portfolio, certain water soluble products, and related assets on October 31, 2024. Additionally, Zoetis Inc. purchased a manufacturing site outside Atlanta, Georgia in 2023, with commercial production planned for the future.

Geographic Footprint: Zoetis Inc. operates globally, with its business organized into two primary segments: United States (U.S.) and International. The U.S. segment generated $5,097 million in revenue in 2025, representing 54% of total revenue. The International segment contributed $4,254 million, or 45% of total revenue, in the same period. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia, and South America, with products sold in over 100 countries. In 2025, thirteen countries outside the U.S. each contributed over $100 million in revenue, with the U.S. being the only country to exceed 10% of total revenue.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 71.8%
• Operating Margin: 37.5%
• Net Margin: 28.2%

Investment in Growth:

• R&D Expenditure: $698 million (7.4% of revenue)
• Capital Expenditures: $621 million
• Strategic Investments: In 2025, Zoetis Inc. acquired Veterinary Pathology Group. In 2023, the company acquired PetMedix Ltd and adivo GmbH, and purchased a manufacturing site outside Atlanta, Georgia.

Business Segment Analysis

United States (U.S.)

Financial Performance:

• Revenue: $5.10 billion (+0.5% YoY)
• Operating Margin: 67.5%
• Key Growth Drivers: Companion animal revenue growth was primarily driven by increased sales of Simparica Trio, key dermatology products, and small animal diagnostics. Livestock revenue declined due to the impact of the medicated feed additive divestiture, partially offset by higher demand for vaccines in cattle and poultry markets.

Product Portfolio:

• Diversified portfolio for both companion animal and livestock customers.
• Major product lines include Simparica Trio, key dermatology products, and small animal diagnostics for companion animals; and vaccines for cattle and poultry for livestock.

Market Dynamics:

• Companion animal products represented 83% of U.S. revenue.
• Livestock products represented 17% of U.S. revenue.
• The medicated feed additive divestiture negatively impacted livestock revenue across cattle, poultry, and swine products.

International

Financial Performance:

• Revenue: $4.25 billion (+3.7% YoY, +5% operational growth)
• Operating Margin: 53.2%
• Key Growth Drivers: Companion animal operational revenue growth was driven by increased sales of the Simparica franchise, key dermatology products, and monoclonal antibody (mAb) products for osteoarthritis pain (Librela and Solensia). Livestock operational revenue growth was due to increased sales in cattle and fish products, with swine products also increasing due to higher vaccine demand and geographic expansion.

Product Portfolio:

• Diversified portfolio for both companion animal and livestock customers.
• Major product lines include Simparica franchise products, dermatology products, and mAb products for OA pain for companion animals; and vaccines for cattle, fish, and swine for livestock.

Market Dynamics:

• Companion animal products represented 56% of International revenue.
• Livestock products represented 44% of International revenue.
• International segment revenue was positively impacted by operational changes related to the Expected Fiscal Year Alignment, leading to an approximate 2.5% to 3.5% increase in sales in Q4 2025 due to accelerated timing of sales, a trend not expected to recur.
• Foreign exchange unfavorably impacted revenue by approximately $36 million, or 1%.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: In 2025, Zoetis Inc. repurchased 23.9 million shares for $3.2 billion. This included $248 million used to purchase approximately 2.1 million shares concurrently with the December 2025 convertible senior notes offering, and an additional $1,535 million for further repurchases post-offering.
• Dividend Payments: Quarterly cash dividends of $0.50 per share of common stock were paid in fiscal year 2025, totaling $889 million.
• Future Capital Return Commitments: A multi-year share repurchase program of up to $6 billion was authorized in August 2024, with $2.4 billion remaining as of December 31, 2025. The company expects to continue paying dividends consistent with historic payments.

Balance Sheet Position:

• Cash and Equivalents: $2.31 billion
• Total Debt: $9.04 billion
• Net Cash Position: -$6.73 billion (Net Debt)
• Credit Rating: Moody's: P-2 (Commercial Paper), A3 (Long-term Debt), Stable (Outlook). S&P: A-2 (Commercial Paper), BBB+ (Long-term Debt), Stable (Outlook).
• Debt Maturity Profile:
  • 2026: $0 million
  • 2027: $750 million
  • 2028: $1,350 million
  • 2029: $2,000 million
  • 2030: $750 million
  • Thereafter: $4,300 million
  • Total Principal Amount: $9,150 million

Cash Flow Generation:

• Operating Cash Flow: $2.90 billion
• Free Cash Flow: $2.28 billion (Operating Cash Flow less Capital Expenditures)

Operational Excellence

Production & Service Model: Zoetis Inc. operates a global manufacturing network of 21 owned sites across 10 countries, supplemented by over 90 third-party contract manufacturing organizations (CMOs). The company is expanding capabilities at existing sites and plans to begin commercial production at a newly acquired manufacturing site outside Atlanta, Georgia, in the future. Operational philosophy emphasizes efficiency improvements through programs like Six Sigma and Lean capabilities, supported by globally managed quality control and assurance programs.

Supply Chain Architecture: The supply chain relies on a network of owned manufacturing sites and CMOs for product manufacturing. Raw materials are sourced from a variety of third-party suppliers, and logistics service providers are utilized for global shipping and support.

Key Suppliers & Partners:

• Manufacturing Partners: Over 90 CMOs, both centrally and locally managed, contribute to the global manufacturing network.
• Raw Material Suppliers: A diverse base of third-party suppliers provides necessary raw materials.
• Logistics Partners: Third-party logistics service providers are key for shipping and logistics support.

Facility Network:

• Manufacturing: 21 owned sites located in countries including the U.S. (Buellton, Charles City, Durham, Kalamazoo, Lincoln, San Diego, Union City, White Hall), Australia (Melbourne, Rutherford), Belgium (Louvain-la-Neuve), Brazil (Campinas), China (Suzhou), Ireland (Rathdrum, Tallaght, Tullamore), Italy (Catania), New Zealand (Wellington), Norway (Klofta, Overhalla), and Spain (Olot). A new manufacturing site was purchased outside Atlanta, Georgia in 2023.
• Research & Development: R&D headquarters is in Kalamazoo, Michigan, with operations co-located at manufacturing sites in Rutherford (Australia), Louvain-la-Neuve (Belgium), Campinas (Brazil), Suzhou (China), Olot (Spain), Charles City (Iowa, U.S.), Durham (North Carolina, U.S.), Lincoln (Nebraska, U.S.). Additional R&D centers are in Sydney (Australia), Zaventem (Belgium), Beijing (China), Puchheim (Germany), Thane (India), Oslo (Norway), Hong Ngu (Vietnam), Con Tho (Vietnam), Cambridge (U.K.), and Fort Collins (Colorado, U.S.).
• Distribution: Supported by logistics service providers and a network of distributors.

Operational Metrics: The company's safety programs have resulted in strong safety performance, with total injury rate (TIR) and lost time injury rate (LTIR) rates being lower than industry averages.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: A dedicated sales organization, including sales representatives and technical and veterinary operations specialists, directly engages with veterinarians and livestock producers to promote and sell products and services.
• Channel Partners: Third-party veterinary distributors provide logistics and sales and marketing support, particularly in regions without a direct commercial presence.
• Digital Platforms: Increasing investment in direct-to-consumer marketing efforts and sales through internet-based retailers, "big-box" retail stores, and other e-commerce outlets, including online ordering sites in markets like the U.S. and Brazil.

Customer Portfolio: Enterprise Customers:

• Tier 1 Clients: Primary customers include veterinarians, third-party veterinary distributors, and livestock producers (beef and dairy farmers, pork and poultry operators).
• Customer Concentration: Sales to the largest customer, a U.S. veterinary distributor, represented approximately 16% of total revenue in 2025.

Geographic Revenue Distribution:

• United States: 54% of total revenue
• International: 45% of total revenue
• Key International Markets (2025): Brazil ($393 million), Australia ($329 million), United Kingdom ($325 million), Canada ($290 million), Germany ($236 million), China ($227 million), France ($165 million), Mexico ($160 million), Japan ($154 million), Spain ($145 million), Italy ($137 million), Chile ($139 million).

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The animal health industry is a growing, highly competitive sector impacting billions globally. It is characterized by increasing pet owner commitment, economic development, longer companion animal lifespans, and rising demand for animal protein driven by human population growth and living standards. Recent years have seen increased consolidation within the industry.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Boehringer Ingelheim Animal Health Inc.: A major animal health division of Boehringer Ingelheim GmbH, competing across various product categories and species.
• Merck Animal Health: The animal health division of Merck & Co., Inc., offering a broad range of products.
• Elanco Animal Health: A standalone animal health company with a diverse portfolio.
• IDEXX Laboratories: A key competitor in the animal health diagnostics sector.
• Other Competitors: Numerous mid-sized companies and start-ups with specialized focuses, as well as hundreds of other global producers.

Emerging Competitive Threats: Increased industry consolidation, new market entrants, disruptive technologies, lower-cost generic alternatives, "green" or "holistic" health products, and alternative distribution channels such as internet-based retailers and "big-box" stores.

Competitive Response Strategy: Zoetis Inc. focuses on continuous innovation through new chemical, biopharmaceutical, and biological entities, as well as product lifecycle enhancements (new claims, species extensions, formulations, combinations, and market expansion). The company invests in direct-to-consumer marketing, adopts a "One Health" approach for emerging infectious diseases, and collaborates with academic and industry partners (e.g., Colorado State University, Blacksmith Medicines) for R&D. Strategic acquisitions, particularly in diagnostics and biopharmaceuticals, further strengthen its competitive stance.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The highly competitive animal health industry, coupled with customer and distributor consolidation, could negatively impact product pricing. Changes in companion animal product distribution channels (e.g., increased e-commerce) may reduce market share and margins. Outbreaks of animal infectious diseases can adversely affect livestock product sales and production. Disruptive innovations, advances in medical practices, and alternative health products (e.g., "green" products) could negatively impact product markets. Growing restrictions or consumer preferences against antibacterials in food-producing animals, or perceived adverse effects of products on food-derived from animals, could reduce demand. Increased regulation or decreased governmental support for the livestock industry may also reduce product demand. Technology Disruption: The market for Zoetis Inc.'s products could be negatively impacted by the introduction of newly developed or alternative products, including "green" or "holistic" health products, or by technological breakthroughs from competitors that could render existing technologies obsolete. Customer Concentration: The company's reliance on a single U.S. veterinary distributor, which accounted for approximately 16% of total revenue in 2025, poses a concentration risk. Discontinuation of relationships with large customers due to economic conditions, public health crises, or sanctions could materially adversely affect operating results.

Operational & Execution Risks

Supply Chain Vulnerabilities: Manufacturing problems, capacity imbalances, and reliance on sole-source manufacturing sites or third-party CMOs can lead to product launch delays, inventory shortages, recalls, or unanticipated costs. Disruptions from third-party suppliers (e.g., due to geopolitical tensions, financial distress, or contract disputes) could hinder production and product availability. Geographic Concentration: Outbreaks of highly contagious diseases near main production sites could necessitate immediate production halts or increased raw material procurement expenses. Capacity Constraints: The unpredictability of product success, long lead times for complex manufacturing site construction, and shifting customer demand can lead to capacity imbalances, potentially affecting the ability to meet demand or resulting in excess capacity.

Financial & Regulatory Risks

Market & Financial Risks: Global economic and political conditions, including ongoing conflicts, economic weakness in China, and inflation, pose risks to operating results, financial condition, and liquidity. Foreign exchange rate fluctuations and potential currency controls, particularly in emerging markets, can impact reported financial results. The company's substantial indebtedness (approximately $9.04 billion as of December 31, 2025) could limit financial flexibility and increase vulnerability to adverse economic conditions. Regulatory & Compliance Risks: The business is subject to extensive and evolving state, federal, and international laws and regulations governing product development, manufacturing, marketing, and sale. Non-compliance or new regulations could result in fines, production shutdowns, product withdrawals, or civil/criminal prosecution. Delays in regulatory approvals for new products or changes to existing products can negatively impact growth. Compliance with complex and evolving data privacy laws (e.g., GDPR, China's PIPL) and AI regulations is costly and critical to reputation. Environmental, health, and safety laws, including those related to PFAS, can lead to remediation costs, fines, or operational curtailment.

Geopolitical & External Risks

Geopolitical Exposure: A significant portion of operations in foreign jurisdictions exposes the company to economic, political, legal, and business environment risks, including volatility in financial markets, difficulties enforcing intellectual property rights, and political/social instability. Trade Relations: Changes in trade policies, such as new quotas, duties, tariffs, or economic sanctions, can adversely affect the ability to register products, source materials, sell goods, or conduct business in certain markets. Retaliatory trade policies or anti-U.S. sentiment could also impact customer engagement and regulatory scrutiny. Sanctions & Export Controls: Compliance with foreign trade controls and economic sanctions (e.g., OFAC, EU) is critical, particularly for limited humanitarian sales to countries like Russia and Iran. Violations could lead to significant penalties and reputational damage.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas: Zoetis Inc.'s R&D focuses on the discovery and development of new chemical, biopharmaceutical, and biological entities, alongside extensive product lifecycle innovation. Key areas include vaccines, pharmaceuticals, diagnostics, genetics, biodevices, and digital/data analytics, all aimed at predicting, preventing, detecting, and treating animal health conditions across all core species. Innovation Pipeline: The R&D pipeline comprises over 300 programs, with a majority dedicated to new product development. R&D spending is prioritized annually based on strategic fit, technical feasibility, return on investment, and customer/market needs.

Intellectual Property Portfolio:

• Patent Strategy: The company holds over 5,500 granted patents and 1,600 pending patent applications in over 50 countries, focusing on major markets. It vigorously protects, enforces, and defends its IP rights, including through litigation.
• Licensing Programs: Zoetis Inc. engages in collaborations and licensing arrangements with third parties to access molecules, compounds, and technologies.
• IP Litigation: The company is regularly involved in patent litigation and other IP claims, which are costly and time-consuming, and could impact business and financial condition if resolved adversely.

Technology Partnerships:

• Strategic Alliances: Zoetis Inc. collaborates with academic and industry partners to drive innovation. Notable partnerships include Colorado State University (for immunomodulators in livestock and companion animal disease biology) and Blacksmith Medicines (for novel antibiotic discovery).
• Research Collaborations: The company regularly enters agreements with external parties for research programs and access to new devices and technologies.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company relies on its executive officers and key personnel, including R&D, technical, legal, regulatory, sales, security, marketing, manufacturing, and administrative staff. Recruitment and retention are influenced by compensation, benefits, work location, and environment.

Board Composition: The Board of Directors actively oversees material risks, with the Audit Committee specifically responsible for enterprise risk management and information security risk management programs.

Human Capital Strategy

Workforce Composition:

• Total Employees: Approximately 14,500 employees worldwide as of December 31, 2025.
• Geographic Distribution: Approximately 6,800 employees in the U.S. and 7,700 in other jurisdictions.
• Skill Mix: The R&D team actively recruits scientists and research and development personnel from universities and scientific forums.

Talent Management: Acquisition & Retention: Zoetis Inc. employs various career development, employee benefits, policies, and compensation programs to attract, develop, and retain talent. The global voluntary attrition rate decreased to 7% in 2025 from 8% in 2024. Employee Value Proposition: Compensation and benefits programs are designed to support overall colleague well-being, including physical and mental health, financial wellness, and family/lifestyle resources. U.S. benefits include flexible work arrangements, educational assistance, mental health support, pet care benefits, and inclusive family-friendly benefits such as fully paid parental leave, fertility, and surrogacy benefits.

Diversity & Development:

• Development Programs: Internal programs include a talent development portal, mentoring, career planning resources, leadership development, and performance management and training.
• Culture & Engagement: The company's engagement rate was 87% in 2025, maintaining high levels for the past five years. Eight Colleague Resource Groups foster an inclusive environment.

Environmental & Social Impact

Environmental Commitments: Climate Strategy: Zoetis Inc.'s "Driven to Care" sustainability program includes aspirations and goals related to protecting the planet and reducing its environmental footprint. Supply Chain Sustainability: The Global Environmental Health and Safety (EHS) Policy standards define EHS performance requirements for all sites, procedures, and recommended practices.

Social Impact Initiatives:

• Community Investment: The "Driven to Care" program aims to improve access to care for animals and support the veterinary profession.
• Product Impact: The company leverages its innovation capabilities to develop solutions that improve productivity, keep animals healthy, and combat emerging infectious diseases.

Business Cyclicality & Seasonality

Demand Patterns:

• Seasonal Trends: Demand for many animal health products is influenced by weather conditions and weather-related pressures from pests (e.g., ticks), leading to regional and seasonal fluctuations in results.
• Economic Sensitivity: Growth in both companion animal and livestock sectors is driven by overall economic development and rising living standards, particularly in emerging markets. Demand for Zoetis Inc.'s products has historically been more stable than other production inputs, as product costs are small relative to other livestock production costs.
• Industry Cycles: Long-term growth drivers for livestock products include human population growth, increasing demand for animal protein, natural resource constraints driving productivity needs, increasing urbanization, and a heightened focus on food safety and security.

Planning & Forecasting: Not explicitly detailed in the filing.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations: The sale of animal health products is governed by specific laws and regulations in each jurisdiction. Key regulatory bodies include the U.S. FDA (Center for Veterinary Medicine for pharmaceuticals, Center for Devices and Radiological Health for human medical devices), USDA (Center for Veterinary Biologics for biological products), and EPA (Office of Pesticide Programs for veterinary pesticides). Internationally, the European Medicines Agency (EMA) in the EU, the U.K.'s Veterinary Medicines Directorate (VMD), China's Ministry of Agriculture and Rural Affairs (MARA), Brazil's Ministry of Agriculture, Livestock and Food Supply (MAPA), and the Australian Pesticides and Veterinary Medicines Authority (APVMA) oversee product approvals and compliance. International Compliance: The company adheres to international harmonization efforts like the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products (VICH). It also complies with global data privacy regulations such as the EU GDPR, U.K. GDPR, Brazilian General Data Protection Law, China’s Personal Information Protection Law, and India's Digital Personal Data Protection Act.

Trade & Export Controls:

• Export Restrictions: Zoetis Inc. is subject to U.S. foreign trade controls (e.g., FCPA, Commerce Department's Bureau of Industry and Security, OFAC) and similar international regulations that restrict activities with certain countries, governments, entities, and individuals.
• Sanctions Compliance: The company conducts limited humanitarian animal health product sales to Russia and Iran in accordance with general and specific licenses issued by OFAC and EU Member States, adhering to corporate policies.

Legal Proceedings: Zoetis Inc. is subject to various legal proceedings in the ordinary course of business, including product liability, commercial, patent, and environmental litigation, as well as government investigations. While management believes the likelihood of a material adverse effect on consolidated results, financial condition, or cash flows from current proceedings is remote, litigation is inherently unpredictable. One specific ongoing matter involves a complaint filed by the Municipality of Ulianopolis (Brazil) in 2012 against a Zoetis entity and other companies regarding environmental impacts from a waste incineration facility.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The effective tax rate was 20.4% in 2025, 20.3% in 2024, and 20.3% in 2023. The 2025 rate was primarily influenced by a lower benefit in the U.S. related to foreign-derived intangible income, partially offset by a more favorable jurisdictional mix of earnings and higher net discrete tax benefits.
• Geographic Tax Planning: The company generally intends to permanently reinvest the majority of earnings from non-U.S. subsidiaries. An initiative to maximize U.S. cash position in 2022 and 2024 involved prepayments from a related foreign entity in Belgium, qualifying as foreign-derived intangible income, with benefits deferred to subsequent years.
• Tax Reform Impact: The U.S. One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, is not expected to have a material impact on financial results, effective tax rate, or deferred tax assets/liabilities in 2025 and future periods. The company is monitoring the OECD's work on global minimum tax (Pillar Two) and profit allocation (Pillar One), which could impact its effective tax rate.

Tax Audits: Zoetis Inc. is currently under income tax audit by the U.S. IRS for tax years 2017-2018. In September 2024, the IRS issued a Revenue Agent Report proposing an additional tax liability of approximately $450 million (excluding interest and penalties) related to the one-time mandatory deemed repatriation tax from 2018. The company disagrees with the IRS's position and intends to defend its tax return. Open audit years also exist in major foreign jurisdictions including Canada (2022-2025), Asia-Pacific (2015-2025), Europe (2013-2025), and Latin America (2016-2025).

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: Zoetis Inc. maintains cybersecurity insurance coverage, though costs related to cybersecurity threats or disruptions may not be fully insured.
• Risk Transfer Mechanisms: The company utilizes foreign exchange derivative instruments, such as net investment hedges and foreign currency forward-exchange contracts, to manage foreign currency risks. Interest rate swap contracts are also used to manage interest rate exposure and reduce borrowing costs, including forward-starting interest rate swaps (cash flow hedges) and fixed-to-floating interest rate swaps (fair value hedges).